The partnership deals just keep rolling in for Halozyme Therapeutics’ drug delivery technology.
Gossamer Bio — a closely watched San Diego biotech during the government shutdown — made its public debut Feb. 8 with an upsized $276 million offering.
The government shutdown ended Jan. 25, but lingering effects are evident in San Diego life sciences, from a halted merger to initial public offerings.
The U.S. Food and Drug Administration granted orphan drug designations to San Diego-based Equillium’s drug candidate for the prevention and treatment of a tissue disease.
FINANCE: Investors See Pluses In Past Success, Experience
San Diego biotech’s growing roster of rising stars and veteran leaders helped propel the region to new fundraising heights in 2018, observers say.
San Diego biotech Neurocrine’s fourth quarter earnings largely beat analyst expectations.
In the first biotech initial public offering of the year, La Jolla-based INmune Bio took in $8.16 million during its trading debut. The Nasdaq listing also raised the profile of what’s been a quiet operation.
Halozyme has licensed its drug delivery technology to yet another company.
San Diego-based Nanomedical Diagnostics is now known as Cardea.
With the government shutdown over, Gossamer Bio will take a traditional path to an initial public offering, abandoning a plan to sidestep the U.S. Securities and Exchange Commission.
Private equity firm Advent International bought a majority stake in San Diego-headquartered BioDuro for an undisclosed amount, according to a recent announcement.
San Diego lab rents in the prior four years were consistently lower than the country’s two larger life sciences markets, San Francisco and Boston.
With the government shutdown over, Gossamer Bio is expected to take a traditional path to an initial public offering, abandoning a plan to sidestep the U.S. Securities and Exchange Commission.
San Diego-based Neurocrine will pay Voyager Therapeutics $165 million upfront as part of a larger pact, it was announced Jan. 29.
Illumina reported an 11 percent increase in fourth quarter revenue after the market closed Jan. 29.